Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761160 · ClinicalTrials.gov registry record · NA
Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT03761160: Completed NA study, sponsored by Dana-Farber Cancer Institute.
NCT03761160 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03761160, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits.
Primary Outcome
This endpoint will be assessed with dual-energy x-ray absorptiometry - also known as a DEXA scan.
Interventions
- OTHER Usual care
- OTHER Mobile Health App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-07-16 |
| Est. Completion | 2020-07-10 |
| Phase | NA |
What the finished NCT03761160 record still lists
NCT03761160 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Usual care is the first listed.
NCT03761160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03761160 about?
NCT03761160 is a clinical study titled "Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy". This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits.
What is the current status of trial NCT03761160?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2019-07-16. Estimated completion is 2020-07-10.
What interventions are being tested in trial NCT03761160?
The interventions under investigation include: Usual care (OTHER), Mobile Health App (OTHER).
Who is sponsoring clinical trial NCT03761160?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03761160's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI